In this PDX cohort, we demonstrate enhanced anti-tumor responses to cisplatin in HNSCC PDXs with higher C19orf57 expression, which underscores the translational relevance of our transcriptomic findings in this PDX collection. The gene discussed is BRME1; the disease is neoplasm.